|
G |
Crp |
C-reactive protein |
affects expression |
ISO |
acalabrutinib affects the expression of CRP protein |
CTD |
PMID:32503877 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions affects metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of acalabrutinib Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of acalabrutinib] |
CTD |
PMID:34153224 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
acalabrutinib results in decreased expression of IL6 protein |
CTD |
PMID:32503877 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
affects binding |
ISO |
acetoacetyl CoA binds to HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
|
G |
Acly |
ATP citrate lyase |
increases abundance |
ISO |
ACLY protein results in increased abundance of Acetyl Coenzyme A |
CTD |
PMID:28077572 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
App |
amyloid beta precursor protein |
affects localization increases secretion multiple interactions |
ISO |
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 PMID:22906069 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases activity |
EXP |
Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein |
CTD |
PMID:8075222 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
Acetyl Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:30213948 |
|
NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions affects binding |
ISO |
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein |
CTD |
PMID:20545351 PMID:22835378 |
|
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]; afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein] |
CTD |
PMID:28787001 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases activity decreases phosphorylation |
ISO |
afatinib results in decreased activity of EGFR protein; afatinib results in decreased activity of EGFR protein mutant form afatinib results in decreased phosphorylation of EGFR protein |
CTD |
PMID:21322567 PMID:22242139 PMID:28787001 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
multiple interactions |
ISO |
afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein] |
CTD |
PMID:28787001 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
decreases expression |
ISO |
afatinib results in decreased expression of IKBKB protein |
CTD |
PMID:22242139 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
decreases phosphorylation |
ISO |
Afatinib results in decreased phosphorylation of IQGAP1 protein |
CTD |
PMID:33087447 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
Afatinib inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA] |
CTD |
PMID:31944254 |
|
NCBI chr 1:196,864,375...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:22242139 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression multiple interactions |
ISO |
afatinib results in decreased expression of POU5F1 protein afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein] |
CTD |
PMID:28787001 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:22242139 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
amperozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:19583963 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Agrp |
agouti related neuropeptide |
decreases expression |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of AGRP mRNA |
CTD |
PMID:26468265 |
|
NCBI chr19:33,447,992...33,523,068
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
arachidonyl-2-chloroethylamide results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:26847930 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT1 protein] |
CTD |
PMID:26467187 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT2 protein] |
CTD |
PMID:26467187 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA] |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein |
CTD |
PMID:30607903 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cartpt |
CART prepropeptide |
decreases expression multiple interactions |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:31256211 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:31256211 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Cd86 |
CD86 molecule |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP ISO |
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein] |
CTD |
PMID:12734338 PMID:27455076 PMID:29033935 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions increases expression |
ISO |
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein |
CTD |
PMID:31912162 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] |
CTD |
PMID:31912162 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein] |
CTD |
PMID:31256211 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of DRD2 mRNA |
CTD |
PMID:22791651 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases expression multiple interactions |
ISO EXP |
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] |
CTD |
PMID:27455076 PMID:30019168 PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
multiple interactions increases expression |
ISO |
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression increases secretion multiple interactions |
ISO EXP |
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein |
CTD |
PMID:27455076 |
|
NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:26847930 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC protein]]] |
CTD |
PMID:26847930 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein] |
CTD |
PMID:26671069 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases expression |
EXP |
arachidonyl-2-chloroethylamide results in increased expression of HCRT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr10:85,689,992...85,691,206
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein] |
CTD |
PMID:32033504 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein] |
CTD |
PMID:29033935 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein] |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:31256211 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
multiple interactions increases expression |
EXP |
arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA] arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions decreases expression |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA] arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein] |
CTD |
PMID:29033935 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions increases activity |
ISO |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein] |
CTD |
PMID:29033935 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein] |
CTD |
PMID:29033935 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased phosphorylation of TRP53 protein] |
CTD |
PMID:31256211 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:26467187 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions |
ISO |
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein] |
CTD |
PMID:26467187 |
|
NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
asperphenamate analog binds to and results in decreased activity of CTSL protein |
CTD |
PMID:30253340 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
asperphenamate analog binds to and results in decreased activity of CTSS protein |
CTD |
PMID:30253340 |
|
NCBI chr 2:183,089,192...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
bictegravir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
increases expression |
ISO |
bictegravir results in increased expression of CYP26A1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
bictegravir results in increased expression of FGF8 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Mixl1 |
Mix paired-like homeobox 1 |
increases expression |
ISO |
bictegravir results in increased expression of MIXL1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065
|
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
butyryl-coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
Carboxin results in decreased expression of ANXA2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
decreases expression |
ISO |
Carboxin results in decreased expression of BBC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
CDN1163 inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MTTP protein] |
CTD |
PMID:34516972 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
copanlisib results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31445927 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Fas |
Fas cell surface death receptor |
affects response to substance |
ISO |
copanlisib affects the susceptibility to FAS protein |
CTD |
PMID:31445927 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance |
ISO |
copanlisib results in increased susceptibility to TNF protein |
CTD |
PMID:31445927 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions affects metabolic processing |
ISO |
Quinidine affects the reaction [CYP2D6 protein polymorphism affects the metabolism of dacomitinib] |
CTD |
PMID:34936353 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:27491023 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
DDR1-IN-1 inhibits the reaction [collagen increases DDR1 autophosphorylation in human cell lines] DDR1-IN-1 decreases DDR1 phosphorylation in human cancer cells in mouse model DDR1-IN-1 inhibits the reaction [collagen increases phosphorylation of DDR1 in human melanoma cells] |
RGD |
PMID:23899692 PMID:26719540 PMID:31271515 |
RGD:152995467, RGD:11520844, RGD:151347864 |
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
multiple interactions |
ISO |
DDR1-IN-2 inhibits the reaction [collagen increases DDR1 autophosphorylation in human cell lines] |
RGD |
PMID:23899692 |
RGD:152995467 |
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[decanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
dolutegravir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Cdx1 |
caudal type homeo box 1 |
decreases expression |
ISO |
dolutegravir results in decreased expression of CDX1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr18:54,472,448...54,499,799
Ensembl chr18:54,473,444...54,490,814
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
dolutegravir results in decreased expression of CYP26A1 mRNA dolutegravir results in increased expression of CYP26A1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
dolutegravir results in increased expression of FGF8 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:244,584,477...244,590,359
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Hoxb1 |
homeo box B1 |
increases expression |
ISO |
dolutegravir results in increased expression of HOXB1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836
|
|
G |
Hoxb9 |
homeo box B9 |
decreases expression |
ISO |
dolutegravir results in decreased expression of HOXB9 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
decreases expression |
ISO |
dolutegravir results in decreased expression of MEOX1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
increases expression |
ISO |
dolutegravir results in increased expression of MESP2 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mixl1 |
Mix paired-like homeobox 1 |
increases expression |
ISO |
dolutegravir results in increased expression of MIXL1 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065
|
|
G |
Tbx6 |
T-box transcription factor 6 |
increases expression |
ISO |
dolutegravir results in increased expression of TBX6 mRNA |
CTD |
PMID:34515794 |
|
NCBI chr 1:181,387,851...181,392,762
Ensembl chr 1:181,388,684...181,392,593
|
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of perrhenate analog]; dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Iodide analog]; dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Pertechnetate Tc 99m] |
CTD |
PMID:12488351 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
affects hydrolysis |
ISO |
ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
affects hydrolysis |
ISO |
ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
|
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases abundance |
ISO |
HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid |
CTD |
PMID:25061560 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases abundance |
ISO |
POR gene mutant form results in increased abundance of glycolithocholic acid |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] |
CTD |
PMID:17881359 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
glycoursodeoxycholic acid results in decreased expression of EDN1 protein |
CTD |
PMID:15556138 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
ISO |
[glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form |
CTD |
PMID:18188457 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] |
CTD |
PMID:17881359 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]; NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]] |
CTD |
PMID:24912985 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
increases expression |
ISO |
GSK343 results in increased expression of DICER1 mRNA |
CTD |
PMID:25351418 |
|
NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases activity |
ISO |
GSK343 results in decreased activity of EZH2 protein |
CTD |
PMID:23759589 PMID:24900432 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
isobutyryl-coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[lauroyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat results in increased expression of BAK1 protein] |
CTD |
PMID:30205152 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein] |
CTD |
PMID:30205152 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat results in decreased expression of CCND1 protein] |
CTD |
PMID:30205152 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat affects the localization of CTNNB1 protein]; LGK974 inhibits the reaction [Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein] |
CTD |
PMID:30205152 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat results in increased transport of DIABLO protein] |
CTD |
PMID:30205152 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat results in increased transport of HTRA2 protein] |
CTD |
PMID:30205152 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
LGK974 inhibits the reaction [Paraquat results in increased cleavage of PARP1 protein] |
CTD |
PMID:30205152 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
manumycin inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19002579 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
manumycin results in increased activity of CASP3 [Quercetin co-treated with manumycin] results in decreased expression of CASP3 protein; Acetylcysteine inhibits the reaction [manumycin results in increased activity of CASP3] |
CTD |
PMID:14625852 PMID:19409983 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
manumycin inhibits the reaction [Plant Extracts results in decreased expression of CCNB1 mRNA] |
CTD |
PMID:25051199 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased expression of CCND1 protein] |
CTD |
PMID:19409983 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
manumycin inhibits the reaction [Plant Extracts results in decreased expression of CDC25C mRNA] |
CTD |
PMID:25051199 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased expression of CDKN1A protein] manumycin results in increased expression of CDKN1A protein |
CTD |
PMID:19409983 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chrna5 |
cholinergic receptor nicotinic alpha 5 subunit |
multiple interactions |
ISO |
manumycin inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; manumycin inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; manumycin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CHRNA5 mRNA]; manumycin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CHRNA5 protein] |
CTD |
PMID:18450646 |
|
NCBI chr 8:55,369,794...55,398,526
Ensembl chr 8:55,369,794...55,398,146
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
manumycin inhibits the reaction [Acetaminophen results in increased expression of CYBB mRNA] |
CTD |
PMID:19739265 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Enosf1 |
enolase superfamily member 1 |
decreases expression affects localization |
ISO |
manumycin results in decreased expression of ENOSF1 protein manumycin affects the localization of ENOSF1 protein |
CTD |
PMID:18357371 |
|
NCBI chr 9:113,275,267...113,314,842
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
manumycin inhibits the reaction [Acetaminophen results in increased expression of FASL mRNA] |
CTD |
PMID:19739265 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
manumycin inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; manumycin inhibits the reaction [Pyruvaldehyde results in increased expression of FN1 mRNA] |
CTD |
PMID:16572112 PMID:17635749 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
manumycin inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; manumycin inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; manumycin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of GATA2 mRNA]; manumycin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of GATA2 protein] |
CTD |
PMID:18450646 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in increased phosphorylation of H2AX protein] |
CTD |
PMID:19409983 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions decreases expression |
ISO EXP |
manumycin inhibits the reaction [Acetaminophen results in increased activity of HRAS protein] manumycin inhibits the reaction [Glucose results in increased activity of HRAS protein]; manumycin inhibits the reaction [INS1 protein results in increased farnesylation of HRAS protein] manumycin results in decreased expression of HRAS protein |
CTD |
PMID:16572112 PMID:19002579 PMID:19739265 PMID:19958823 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
manumycin inhibits the reaction [Acetaminophen results in increased expression of IFNG mRNA]; manumycin inhibits the reaction [Acetaminophen results in increased expression of IFNG protein] |
CTD |
PMID:19739265 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] |
CTD |
PMID:21430599 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases response to substance |
ISO |
manumycin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; manumycin inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] manumycin results in decreased susceptibility to IL1B protein |
CTD |
PMID:21211511 PMID:21430599 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions decreases activity |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased activity of KRAS protein] |
CTD |
PMID:19409983 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
manumycin inhibits the reaction [zinc chloride results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21575692 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
manumycin inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:19739265 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
manumycin inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:19739265 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
manumycin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; manumycin inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; manumycin inhibits the reaction [TNF protein results in increased expression of MMP13 mRNA]; manumycin inhibits the reaction [TNF protein results in increased expression of MMP13 protein] |
CTD |
PMID:21211511 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mras |
muscle RAS oncogene homolog |
multiple interactions |
EXP |
manumycin inhibits the reaction [Glucose results in increased activity of MRAS protein] |
CTD |
PMID:18569938 |
|
NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
manumycin inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA]; manumycin inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein] |
CTD |
PMID:19739265 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
manumycin results in increased cleavage of PARP1; manumycin results in increased cleavage of PARP1 protein Acetylcysteine inhibits the reaction [manumycin results in increased cleavage of PARP1]; Quercetin promotes the reaction [manumycin results in increased cleavage of PARP1 protein] |
CTD |
PMID:14625852 PMID:19409983 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
manumycin inhibits the reaction [Streptozocin results in increased expression of RAF1 protein]; manumycin inhibits the reaction [zinc chloride results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:18569938 PMID:21575692 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rasgrf1 |
RAS protein-specific guanine nucleotide-releasing factor 1 |
multiple interactions |
EXP |
manumycin inhibits the reaction [INS1 protein results in increased expression of RASGRF1 protein] |
CTD |
PMID:19002579 |
|
NCBI chr 8:90,445,154...90,574,274
Ensembl chr 8:90,445,154...90,574,269
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased expression of SOD1] |
CTD |
PMID:19409983 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:19409983 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased expression of TERT protein] |
CTD |
PMID:19409983 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
manumycin inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16572112 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases response to substance |
ISO |
manumycin inhibits the reaction [TNF protein results in increased expression of MMP13 mRNA]; manumycin inhibits the reaction [TNF protein results in increased expression of MMP13 protein] geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; manumycin inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; manumycin inhibits the reaction [Acetaminophen results in increased expression of TNF protein] manumycin results in decreased susceptibility to TNF protein |
CTD |
PMID:19739265 PMID:21211511 PMID:21430599 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnpo1 |
transportin 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [manumycin results in decreased expression of TNPO1] |
CTD |
PMID:19409983 |
|
NCBI chr 2:30,207,529...30,300,162
Ensembl chr 2:30,211,510...30,300,375
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
ISO |
manumycin results in decreased expression of TXN |
CTD |
PMID:19409983 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
manumycin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; manumycin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein] |
CTD |
PMID:18569938 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Areg |
amphiregulin |
multiple interactions |
ISO |
marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein] |
CTD |
PMID:15342401 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Grp |
gastrin releasing peptide |
multiple interactions |
ISO |
marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein]; marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein] |
CTD |
PMID:15342401 |
|
NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK1 protein] |
CTD |
PMID:15574683 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK3 protein] |
CTD |
PMID:15574683 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
marimastat inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK8 protein] |
CTD |
PMID:15574683 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
marimastat inhibits the reaction [Oxygen deficiency results in increased expression of MMP2 protein] |
CTD |
PMID:22340517 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein] |
CTD |
PMID:15342401 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
|
G |
Dbi |
diazepam binding inhibitor |
affects binding |
ISO |
S-tetradecanoyl-coenzyme A binds to DBI protein |
CTD |
PMID:17044054 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Drd2 |
dopamine receptor D2 |
affects response to substance affects binding multiple interactions |
ISO EXP |
DRD2 promoter polymorphism affects the susceptibility to nemonapride nemonapride binds to DRD2 protein Cinnarizine inhibits the reaction [nemonapride binds to DRD2 protein]; Flunarizine inhibits the reaction [nemonapride binds to DRD2 protein] |
CTD |
PMID:7503767 PMID:11505224 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd4 |
dopamine receptor D4 |
affects binding |
ISO |
nemonapride binds to DRD4 protein |
CTD |
PMID:31323226 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP3 protein]] |
CTD |
PMID:33309544 PMID:35395232 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP8 protein]] |
CTD |
PMID:35395232 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP9 protein]] |
CTD |
PMID:33309544 PMID:35395232 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
ISO |
[4-amylcinnamoylanthranilic acid results in decreased activity of SLC13A2 protein] which results in decreased susceptibility to diethylene glycol metabolite |
CTD |
PMID:21856646 |
|
NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions decreases activity |
ISO EXP |
4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]] 4-amylcinnamoylanthranilic acid results in decreased activity of TRPM2 protein 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] |
CTD |
PMID:18204483 PMID:30229906 PMID:33309544 PMID:34958835 PMID:35395232 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
|
G |
Mthfs |
methenyltetrahydrofolate synthetase |
affects binding |
ISO |
N-acetyldopamine binds to MTHFS protein |
CTD |
PMID:17055997 |
|
NCBI chr 8:89,729,498...89,801,998
Ensembl chr 8:89,729,508...89,799,089
|
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions affects binding |
ISO |
N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein] N-benzoylalanine binds to THRB protein |
CTD |
PMID:31566444 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:30639138 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
hippuric acid inhibits the reaction [ABCC4 protein results in increased export of Methotrexate] |
CTD |
PMID:21483698 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
hippuric acid inhibits the reaction [ABCG2 protein results in increased export of estrone sulfate] |
CTD |
PMID:21483698 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of hippuric acid |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
hippuric acid results in increased expression of SLC10A1 mRNA |
CTD |
PMID:30639138 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
increases expression |
ISO |
N-methylolacrylamide results in increased expression of ACSM1 mRNA |
CTD |
PMID:17311802 |
|
NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
N-methylolacrylamide results in increased expression of CES1 mRNA |
CTD |
PMID:17311802 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
ISO |
N-methylolacrylamide results in decreased expression of EPHX1 mRNA |
CTD |
PMID:17311802 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
N-methylolacrylamide results in increased activity of NFE2L2 protein |
CTD |
PMID:30114225 PMID:30203046 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
N-methylolacrylamide results in increased expression of NQO1 mRNA |
CTD |
PMID:17311802 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
decreases activity |
ISO |
N-methylolacrylamide results in decreased activity of STAT5B protein |
CTD |
PMID:30114225 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
N-oleoyldopamine binds to and results in increased activity of CNR1 protein |
CTD |
PMID:12569099 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein] |
CTD |
PMID:12569099 PMID:15615864 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
ISO |
Niclosamide results in decreased expression of ACACA mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ACSL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of ACTA2 protein] Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of ACTA2 protein] |
CTD |
PMID:26643609 PMID:28318631 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
decreases expression |
ISO |
Niclosamide results in decreased expression of ADH4 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [Thioacetamide results in increased expression of AFP protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of AFP protein]] |
CTD |
PMID:32961231 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases cleavage |
ISO |
Niclosamide results in increased cleavage of AIFM1 protein |
CTD |
PMID:22576131 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of AKT1 mRNA Niclosamide inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:20215516 PMID:26792726 PMID:29843133 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALDH1A1 protein |
CTD |
PMID:24736023 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
increases expression |
ISO |
Niclosamide results in increased expression of ALDOB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALDOC mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
increases expression multiple interactions decreases response to substance |
ISO |
Niclosamide results in increased expression of ALOX12B mRNA TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA] ALOX12B protein results in decreased susceptibility to Niclosamide |
CTD |
PMID:30258081 |
|
NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions decreases response to substance increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA] ALOX5 protein results in decreased susceptibility to Niclosamide |
CTD |
PMID:30258081 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression |
ISO |
Niclosamide results in decreased expression of ALPL mRNA |
CTD |
PMID:28824321 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apof |
apolipoprotein F |
decreases expression |
ISO |
Niclosamide results in decreased expression of APOF mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO |
[enzalutamide co-treated with Niclosamide] results in decreased expression of AR protein; [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]] which results in decreased expression of KLK3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein alternative form]; bicalutamide promotes the reaction [Niclosamide results in decreased expression of AR protein]; Niclosamide inhibits the reaction [AR protein alternative form binds to KLK3 promoter]; Niclosamide inhibits the reaction [AR protein alternative form results in decreased susceptibility to enzalutamide]; Niclosamide inhibits the reaction [AR protein alternative form results in increased expression of KLK3 mRNA]; Niclosamide inhibits the reaction [AR protein alternative form results in increased expression of KLK3 protein]; Niclosamide inhibits the reaction [AR protein binds to KLK3 promoter]; Niclosamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Niclosamide results in decreased expression of and results in increased degradation of AR protein alternative form Niclosamide results in decreased expression of AR protein; Niclosamide results in decreased expression of AR protein alternative form |
CTD |
PMID:24740322 PMID:25970160 PMID:28500234 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
Niclosamide analog results in decreased expression of ARAF protein; Niclosamide results in decreased expression of ARAF protein |
CTD |
PMID:28284560 |
|
NCBI chr X:1,227,392...1,292,356
Ensembl chr X:1,227,392...1,239,073
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
Niclosamide results in decreased expression of ASF1B mRNA |
CTD |
PMID:28284560 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of ATF3 mRNA; Niclosamide results in increased expression of ATF3 protein ATF3 protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; ATF3 protein affects the reaction [Niclosamide results in increased expression of DDIT3 mRNA]; ATF3 protein affects the reaction [Niclosamide results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:26917416 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Niclosamide results in increased expression of ATF4 mRNA; Niclosamide results in increased expression of ATF4 protein |
CTD |
PMID:26917416 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
ISO |
Niclosamide results in increased expression of ATP5F1A mRNA |
CTD |
PMID:22576131 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5f1d |
ATP synthase F1 subunit delta |
increases expression |
ISO |
Niclosamide results in increased expression of ATP5F1D mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MC3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MF mRNA |
CTD |
PMID:22576131 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5MG mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 8:45,226,750...45,233,582
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP5PB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp6ap1 |
ATPase H+ transporting accessory protein 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ATP6AP1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Niclosamide results in decreased expression of AURKB mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axin2 |
axin 2 |
multiple interactions decreases expression |
ISO |
Niclosamide inhibits the reaction [Lithium Chloride results in increased expression of AXIN2 mRNA] Niclosamide results in decreased expression of AXIN2 mRNA; Niclosamide results in decreased expression of AXIN2 protein |
CTD |
PMID:22576131 PMID:24534281 PMID:24552774 PMID:24736023 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of BAD mRNA |
CTD |
PMID:25988281 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of BAK1 mRNA |
CTD |
PMID:25988281 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions decreases expression |
ISO |
Niclosamide results in increased expression of BAX protein [Niclosamide binds to Polyethyleneimine] which results in increased expression of BAX mRNA; [Niclosamide co-treated with bicalutamide] results in increased expression of BAX protein; bicalutamide inhibits the reaction [Niclosamide results in decreased expression of BAX protein] |
CTD |
PMID:25634333 PMID:25988281 PMID:26703449 PMID:28500234 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:30258081 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Niclosamide analog results in decreased expression of BCL2 protein; Niclosamide results in decreased expression of BCL2 protein [Niclosamide binds to Polyethyleneimine] which results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2 protein]; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2 protein] |
CTD |
PMID:20215516 PMID:23894143 PMID:25634333 PMID:25988281 PMID:26116531 PMID:26703449 PMID:28284560 PMID:28500234 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in decreased expression of BCL2L1 mRNA; bicalutamide promotes the reaction [Niclosamide results in decreased expression of BCL2L1 protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2L1 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of BCL2L1 protein] Niclosamide analog results in decreased expression of BCL2L1 protein; Niclosamide results in decreased expression of BCL2L1 protein |
CTD |
PMID:20215516 PMID:25988281 PMID:26116531 PMID:28284560 PMID:28500234 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of BCL2L2 protein [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] |
CTD |
PMID:23894143 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 protein] |
CTD |
PMID:33632240 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bcl9 |
BCL9, transcription coactivator |
decreases expression |
EXP |
Niclosamide results in decreased expression of BCL9 mRNA |
CTD |
PMID:27338550 |
|
NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions affects expression decreases expression |
ISO |
enzalutamide promotes the reaction [Niclosamide results in decreased expression of BIRC5 protein]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of BIRC5 protein] Niclosamide affects the expression of BIRC5 protein Niclosamide analog results in decreased expression of BIRC5 protein; Niclosamide results in decreased expression of BIRC5 protein |
CTD |
PMID:24552774 PMID:24736023 PMID:25970160 PMID:28284560 PMID:28500234 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of BRAF protein; Niclosamide results in decreased expression of BRAF protein Niclosamide analog results in decreased phosphorylation of BRAF protein |
CTD |
PMID:28284560 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein] |
CTD |
PMID:33524445 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression decreases expression |
ISO EXP |
Niclosamide results in increased cleavage of CASP3 protein Niclosamide inhibits the reaction [Thioacetamide results in decreased expression of CASP3 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in decreased expression of CASP3 mRNA]] [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased expression of CASP3 protein modified form; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form] Niclosamide results in increased expression of CASP3 protein modified form Niclosamide results in decreased expression of CASP3 protein 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine inhibits the reaction [Niclosamide results in increased cleavage of CASP3 protein]; [Niclosamide binds to Polyethyleneimine] which results in increased expression of CASP3 mRNA; ATF3 protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Niclosamide results in increased cleavage of CASP3 protein]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP3 protein]; WNT7A protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:20215516 PMID:21871175 PMID:24750999 PMID:25174399 PMID:25634333 PMID:25988281 PMID:26116531 PMID:26703449 PMID:26917416 PMID:28824321 PMID:29031202 PMID:30258081 PMID:30329025 PMID:32961231 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases expression |
ISO |
bicalutamide promotes the reaction [Niclosamide results in increased expression of CASP7 protein modified form] |
CTD |
PMID:26116531 PMID:28500234 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases cleavage |
ISO |
TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP9 protein] Niclosamide results in increased expression of CASP9 protein modified form |
CTD |
PMID:26116531 PMID:26703449 PMID:30258081 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of CCL2 mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL2 mRNA] |
CTD |
PMID:24561310 PMID:28318631 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of CCL20 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL20 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:24561310 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL5 protein] |
CTD |
PMID:24561310 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCNB1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
EXP ISO |
Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 mRNA]]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CCND1 protein]] Niclosamide results in decreased expression of CCND1 mRNA Niclosamide analog results in decreased expression of CCND1 protein; Niclosamide results in decreased expression of CCND1 mRNA; Niclosamide results in decreased expression of CCND1 protein Niclosamide inhibits the reaction [IL6 protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased expression of CCND1 mRNA]; Niclosamide promotes the reaction [bicalutamide results in decreased expression of CCND1 protein] |
CTD |
PMID:19160421 PMID:20215516 PMID:24552774 PMID:24736023 PMID:26297436 PMID:26964897 PMID:27338550 PMID:28284560 PMID:28500234 PMID:30143678 PMID:32961231 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of CCND2 mRNA Niclosamide results in increased expression of CCND2 mRNA |
CTD |
PMID:22576131 PMID:27226553 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:22576131 PMID:27226553 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD40 protein] |
CTD |
PMID:24561310 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD80 protein] |
CTD |
PMID:24561310 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Lipopolysaccharides affects the expression of CD86 protein] |
CTD |
PMID:24561310 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
CDC37 protein binds to and results in increased susceptibility to Niclosamide analog |
CTD |
PMID:28284560 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression decreases phosphorylation |
ISO |
Niclosamide results in decreased expression of CDC42 mRNA Niclosamide results in decreased phosphorylation of CDC42 protein |
CTD |
PMID:29251334 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDC6 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA2 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdca5 |
cell division cycle associated 5 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA5 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca8 |
cell division cycle associated 8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDCA8 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]; WNT7A protein affects the reaction [Niclosamide results in increased expression of CDH1 protein] Niclosamide results in increased expression of CDH1 mRNA; Niclosamide results in increased expression of CDH1 protein |
CTD |
PMID:25174399 PMID:26643609 PMID:30143678 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CDH2 protein] |
CTD |
PMID:26643609 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK2 protein |
CTD |
PMID:29031202 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDK4 protein |
CTD |
PMID:29031202 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:30258081 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of CDKN3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
increases expression |
ISO |
Niclosamide results in increased expression of CELSR3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
Niclosamide results in decreased expression of CENPA mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cfp |
complement factor properdin |
increases expression |
ISO |
Niclosamide results in increased expression of CFP mRNA |
CTD |
PMID:28284560 |
|
NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Niclosamide results in decreased phosphorylation of and affects the localization of CHUK protein |
CTD |
PMID:26116531 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
Niclosamide results in decreased expression of COL1A1 mRNA |
CTD |
PMID:28824321 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Colec10 |
collectin subfamily member 10 |
increases expression |
ISO |
Niclosamide results in increased expression of COLEC10 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:85,744,895...85,806,368
Ensembl chr 7:85,744,895...85,805,675
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Niclosamide results in increased expression of CREBBP mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of and affects the localization of NFATC1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ITGB3 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of MMP9 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of NFATC1 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OCSTAMP mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OSCAR mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of TRAF6 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK8 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK9 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of NFKBIA protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28824321 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CSGALNACT1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
increases expression |
ISO |
Niclosamide results in increased expression of CSNK1E mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:110,983,322...111,006,926
Ensembl chr 7:110,983,318...111,006,794
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CSRNP1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CTBP1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression decreases expression increases ubiquitination decreases activity multiple interactions |
ISO EXP |
Niclosamide results in increased expression of CTNNB1 mRNA Niclosamide results in decreased expression of CTNNB1 mRNA Niclosamide results in increased ubiquitination of CTNNB1 protein Niclosamide results in decreased activity of CTNNB1 protein Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CTNNB1 protein]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of CTNNB1 protein]] Niclosamide analog results in decreased expression of CTNNB1 protein; Niclosamide results in decreased expression of CTNNB1 protein Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of CTNNB1 protein]; Niclosamide inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein]; Niclosamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein results in increased stability of CTNNB1 protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of CTNNB1 protein] |
CTD |
PMID:19772353 PMID:21531761 PMID:22576131 PMID:24534281 PMID:24552774 PMID:24736023 PMID:25174399 PMID:26964897 PMID:27226553 PMID:27492973 PMID:28284560 PMID:30143678 PMID:32961231 More...
|
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein] |
CTD |
PMID:24534281 |
|
NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
Niclosamide results in decreased expression of CTSC protein |
CTD |
PMID:29480568 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsd |
cathepsin D |
decreases expression |
ISO |
Niclosamide results in decreased expression of CTSD protein |
CTD |
PMID:29480568 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of CXCR5 mRNA] |
CTD |
PMID:33632240 |
|
NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
Niclosamide results in increased expression of CYCS protein |
CTD |
PMID:26703449 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity |
ISO |
Niclosamide results in increased activity of CYP1A1 protein |
CTD |
PMID:12451431 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
Niclosamide results in decreased activity of CYP1A2 protein Niclosamide results in increased expression of CYP1A2 mRNA |
CTD |
PMID:11124226 PMID:28284560 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Niclosamide results in decreased activity of CYP2D6 protein |
CTD |
PMID:11124226 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
ISO |
Niclosamide results in increased expression of CYP39A1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Niclosamide results in decreased activity of CYP3A4 protein |
CTD |
PMID:11124226 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of DDIT3 mRNA; Niclosamide results in increased expression of DDIT3 protein ATF3 protein affects the reaction [Niclosamide results in increased expression of DDIT3 mRNA] |
CTD |
PMID:26917416 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of DECR1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018
|
|
G |
Dmac2l |
distal membrane arm assembly component 2 like |
decreases expression |
ISO |
Niclosamide results in decreased expression of DMAC2L mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 6:88,205,580...88,223,934
Ensembl chr 6:88,205,700...88,223,933
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of DSCC1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dvl1 |
dishevelled segment polarity protein 1 |
increases expression |
ISO |
Niclosamide results in increased expression of DVL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:166,456,989...166,468,733
Ensembl chr 5:166,456,686...166,468,664
|
|
G |
Dvl2 |
dishevelled segment polarity protein 2 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide results in decreased expression of DVL2 protein Niclosamide inhibits the reaction [Thioacetamide results in increased expression of DVL2 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of DVL2 mRNA]] |
CTD |
PMID:19772353 PMID:21531761 PMID:30143678 PMID:32961231 |
|
NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
increases expression |
ISO |
Niclosamide results in increased expression of DVL3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F1 mRNA |
CTD |
PMID:29843133 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f8 |
E2F transcription factor 8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of E2F8 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ebf1 |
EBF transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of EBF1 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
|
|
G |
Echdc1 |
ethylmalonyl-CoA decarboxylase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHDC1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ECHS1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Egf |
epidermal growth factor |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of EGF mRNA; Niclosamide results in decreased expression of EGF protein Niclosamide inhibits the reaction [EGF protein results in increased expression of HIF1A mRNA]; Niclosamide inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30779072 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of EGFR protein; Niclosamide results in decreased expression of EGFR mRNA; Niclosamide results in decreased expression of EGFR protein Niclosamide results in decreased phosphorylation of EGFR protein |
CTD |
PMID:28284560 PMID:28426875 PMID:30779072 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Niclosamide results in increased expression of EGR1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of EIF2AK3 mRNA ATF3 protein affects the reaction [Niclosamide results in increased expression of EIF2AK3 mRNA]; Niclosamide results in increased expression of and results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:26917416 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
Niclosamide results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:26917416 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
Niclosamide promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] |
CTD |
PMID:19771169 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases expression multiple interactions decreases phosphorylation |
ISO |
Niclosamide analog results in decreased expression of EIF4EBP1 protein modified form; Niclosamide results in decreased expression of EIF4EBP1 protein modified form Niclosamide inhibits the reaction [MTOR protein results in increased phosphorylation of EIF4EBP1 protein]; Niclosamide promotes the reaction [EIF4E protein binds to EIF4EBP1 protein] Niclosamide results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:19771169 PMID:28284560 PMID:30258081 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Endod1 |
endonuclease domain containing 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of ENDOD1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 8:11,209,123...11,238,680
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ENO2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Eno3 |
enolase 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ENO3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Niclosamide results in increased expression of EP300 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eps8l3 |
EPS8 like 3 |
increases expression |
ISO |
Niclosamide results in increased expression of EPS8L3 mRNA |
CTD |
PMID:28284560 |
|
Ensembl chr 2:195,514,692...195,528,085
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
decreases expression |
ISO |
Niclosamide results in decreased expression of FAM83D mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO EXP |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of BCL6 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of CXCR5 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL21 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL6 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of PRDM1 mRNA]; Niclosamide affects the reaction [FAS protein mutant form affects the expression of TCF7 protein]; Niclosamide affects the reaction [FAS protein mutant form affects the phosphorylation of STAT3 protein]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FAS mRNA] |
CTD |
PMID:28318631 PMID:33632240 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FGF1 mRNA; Niclosamide results in decreased expression of FGF1 protein |
CTD |
PMID:25174399 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of FKBP5 mRNA Niclosamide results in decreased expression of FKBP5 mRNA |
CTD |
PMID:28500234 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of FN1 protein] HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA] Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Niclosamide results in increased expression of FOSB mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Niclosamide results in increased expression of FOSL1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of FOXM1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of FOXM1 protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of FOXM1 protein] |
CTD |
PMID:27492973 |
|
NCBI chr 4:161,639,561...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fzd1 |
frizzled class receptor 1 |
affects localization |
ISO |
Niclosamide affects the localization of FZD1 protein |
CTD |
PMID:19772353 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzd2 |
frizzled class receptor 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FZD2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
Fzd5 |
frizzled class receptor 5 |
increases expression |
ISO |
Niclosamide results in increased expression of FZD5 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 9:66,117,370...66,119,127
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Fzd9 |
frizzled class receptor 9 |
decreases expression |
ISO |
Niclosamide results in decreased expression of FZD9 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr12:21,427,084...21,429,398
Ensembl chr12:21,427,084...21,429,398
|
|
G |
Gcg |
glucagon |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]; Niclosamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:26964897 |
|
NCBI chr 3:47,113,914...47,122,929
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
increases expression |
ISO |
Niclosamide results in increased expression of GOT2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression decreases phosphorylation |
ISO |
Niclosamide results in decreased expression of GSK3B mRNA Niclosamide results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:22576131 PMID:30143678 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of GTSE1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
ISO |
Niclosamide results in decreased expression of HADH mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression increases expression |
ISO |
Niclosamide results in decreased expression of HAMP mRNA Niclosamide results in increased expression of HAMP mRNA |
CTD |
PMID:25633564 PMID:28284560 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide results in decreased expression of HES1 protein Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HES1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HES1 mRNA]; Niclosamide inhibits the reaction [Thioacetamide results in increased expression of HES1 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of HES1 mRNA]] |
CTD |
PMID:19160421 PMID:28318631 PMID:32961231 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HEY1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY1 mRNA] Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HEY1 mRNA] |
CTD |
PMID:27542212 PMID:28318631 |
|
NCBI chr 2:93,096,706...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
EXP ISO |
Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY2 mRNA] Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:28318631 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of HIF1A mRNA; Niclosamide results in decreased expression of HIF1A protein Niclosamide inhibits the reaction [EGF protein results in increased expression of HIF1A mRNA] |
CTD |
PMID:30779072 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hipk2 |
homeodomain interacting protein kinase 2 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of HIPK2 protein] HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; Niclosamide inhibits the reaction [TGFB1 protein promotes the reaction [SMAD3 protein binds to HIPK2 promoter]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein] |
CTD |
PMID:28318631 |
|
NCBI chr 4:67,439,327...67,619,223
Ensembl chr 4:67,440,501...67,619,223
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
Niclosamide results in decreased expression of HMMR mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hoxa1 |
homeobox A1 |
increases expression |
ISO |
Niclosamide results in increased expression of HOXA1 |
CTD |
PMID:26820057 |
|
NCBI chr 4:81,255,814...81,258,504
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of ICAM1 mRNA] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
affects response to substance |
ISO |
IGF1R protein affects the susceptibility to Niclosamide |
CTD |
PMID:27497986 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igll1 |
immunoglobulin lambda-like polypeptide 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of IGLL1 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr11:84,138,847...84,142,238
Ensembl chr11:84,138,910...84,142,216
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
affects localization |
ISO |
Niclosamide affects the localization of IKBKB protein |
CTD |
PMID:26116531 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
affects localization |
ISO |
Niclosamide affects the localization of IKBKG protein |
CTD |
PMID:26116531 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [IL6 protein results in increased expression of IL12A mRNA] |
CTD |
PMID:26297436 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA] |
CTD |
PMID:33524445 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il21 |
interleukin 21 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL21 protein]; Niclosamide inhibits the reaction [resiquimod results in increased expression of IL21 protein] |
CTD |
PMID:33632240 |
|
NCBI chr 2:120,119,598...120,126,941
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of IL6 protein]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Niclosamide inhibits the reaction [resiquimod results in increased expression of IL6 protein] Niclosamide inhibits the reaction [IL6 protein results in decreased susceptibility to enzalutamide]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of APPA mRNA]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of BIRC5 protein]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of IL12A mRNA]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of MYC protein]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of SOCS1A mRNA]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of TGFB1A mRNA]; Niclosamide inhibits the reaction [IL6 protein results in increased phosphorylation of and results in increased activity of STAT3 protein] |
CTD |
PMID:24561310 PMID:25970160 PMID:26297436 PMID:28318631 PMID:33632240 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgav |
integrin subunit alpha V |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ITGAV mRNA] |
CTD |
PMID:26792726 |
|
NCBI chr 3:68,838,524...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ITGB3 mRNA] Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ITGB3 mRNA] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions increases phosphorylation increases expression |
EXP ISO |
Niclosamide affects the localization of JUN protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Niclosamide results in increased phosphorylation of JUN protein]]; Acetylcysteine inhibits the reaction [Niclosamide results in increased phosphorylation of JUN protein]; Hydrogen Peroxide promotes the reaction [Niclosamide results in increased phosphorylation of JUN protein]; JUN protein affects the reaction [Niclosamide results in increased cleavage of PARP1 protein] Niclosamide results in increased expression of JUN mRNA |
CTD |
PMID:24750999 PMID:27338550 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
ISO |
Niclosamide results in decreased expression of KIF11 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
Niclosamide results in decreased expression of KIF20A mRNA |
CTD |
PMID:28284560 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of KIFC1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases expression |
ISO |
Niclosamide results in increased expression of LCAT mRNA |
CTD |
PMID:28284560 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldha |
lactate dehydrogenase A |
increases expression |
ISO |
Niclosamide results in increased expression of LDHA mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [Thioacetamide results in increased expression of LRP5 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of LRP5 mRNA]] |
CTD |
PMID:32961231 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Lrp6 |
LDL receptor related protein 6 |
decreases expression multiple interactions |
ISO EXP |
Niclosamide analog results in decreased expression of LRP6 protein; Niclosamide results in decreased expression of LRP6 protein Niclosamide inhibits the reaction [Thioacetamide results in increased expression of LRP6 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of LRP6 mRNA]] Niclosamide results in decreased expression of and results in decreased phosphorylation of LRP6 protein |
CTD |
PMID:24552774 PMID:24736023 PMID:28284560 PMID:32961231 |
|
NCBI chr 4:167,266,581...167,400,155
Ensembl chr 4:167,270,353...167,400,497
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Niclosamide results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:30258081 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Niclosamide results in decreased phosphorylation of MAPK1 protein Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24561310 PMID:26116531 PMID:28426875 PMID:28824321 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Niclosamide results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:24561310 PMID:26116531 PMID:28426875 PMID:28824321 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:28824321 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:28824321 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Niclosamide results in decreased expression of MCL1 protein |
CTD |
PMID:20215516 PMID:26116531 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of MCM2 mRNA; Niclosamide results in decreased expression of MCM2 protein |
CTD |
PMID:28284560 PMID:29031202 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Niclosamide results in decreased expression of MCM7 protein |
CTD |
PMID:29031202 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
decreases expression |
EXP |
Niclosamide results in decreased expression of MET mRNA |
CTD |
PMID:27338550 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Niclosamide results in decreased expression of MKI67 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mme |
membrane metallo-endopeptidase |
decreases expression |
ISO |
Niclosamide results in decreased expression of MME mRNA; Niclosamide results in decreased expression of MME protein |
CTD |
PMID:29480568 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of MMP2 mRNA; Niclosamide results in decreased expression of MMP2 protein |
CTD |
PMID:29251334 PMID:30143678 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions decreases expression |
EXP ISO |
Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of MMP7 mRNA] Niclosamide inhibits the reaction [Doxorubicin results in increased expression of MMP7 mRNA] Niclosamide results in decreased expression of MMP7 mRNA |
CTD |
PMID:27338550 PMID:28318631 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of MMP9 mRNA; Niclosamide results in decreased expression of MMP9 protein Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of MMP9 mRNA] |
CTD |
PMID:28824321 PMID:29480568 PMID:30143678 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
Niclosamide results in increased expression of MT2A mRNA |
CTD |
PMID:28284560 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions increases expression |
ISO |
Niclosamide analog results in decreased phosphorylation of MTOR protein; Niclosamide results in decreased phosphorylation of MTOR protein Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein]; Niclosamide inhibits the reaction [MTOR protein results in increased phosphorylation of EIF4EBP1 protein] Niclosamide results in increased expression of MTOR mRNA |
CTD |
PMID:19771169 PMID:26643609 PMID:26703449 PMID:28284560 PMID:29843133 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
EXP ISO |
Niclosamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA] Niclosamide results in decreased expression of MYC mRNA; Niclosamide results in decreased expression of MYC protein [Niclosamide binds to Polyethyleneimine] which results in increased expression of MYC mRNA; [Niclosamide co-treated with bicalutamide] results in decreased expression of MYC mRNA; [Niclosamide co-treated with bicalutamide] results in decreased expression of MYC protein; enzalutamide promotes the reaction [Niclosamide results in decreased expression of MYC protein]; Niclosamide inhibits the reaction [bicalutamide results in increased expression of MYC protein]; Niclosamide inhibits the reaction [IL6 protein results in increased expression of MYC protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of MYC mRNA] |
CTD |
PMID:19160421 PMID:20215516 PMID:22576131 PMID:25970160 PMID:25988281 PMID:26964897 PMID:28500234 PMID:29843133 More...
|
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ndufa10 |
NADH:ubiquinone oxidoreductase subunit A10 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFA10 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 9:93,007,034...93,041,825
Ensembl chr 9:93,007,042...93,042,560
|
|
G |
Ndufa4l2 |
NDUFA4, mitochondrial complex associated like 2 |
increases expression |
ISO |
Niclosamide results in increased expression of NDUFA4L2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:63,351,021...63,359,010
Ensembl chr 7:63,356,883...63,359,010
|
|
G |
Ndufa7 |
NADH:ubiquinone oxidoreductase subunit A7 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFA7 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:14,609,283...14,622,064
Ensembl chr 7:14,609,146...14,631,976
|
|
G |
Ndufa8 |
NADH:ubiquinone oxidoreductase subunit A8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFA8 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 3:19,386,063...19,402,093
Ensembl chr 3:19,386,065...19,402,071
|
|
G |
Ndufb10 |
NADH:ubiquinone oxidoreductase subunit B10 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFB10 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFB6 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181
|
|
G |
Ndufc1 |
NADH:ubiquinone oxidoreductase subunit C1 |
increases expression |
ISO |
Niclosamide results in increased expression of NDUFC1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:135,447,067...135,450,950
Ensembl chr 2:135,447,119...135,450,874
|
|
G |
Ndufs2 |
NADH:ubiquinone oxidoreductase core subunit S2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFS2 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr13:83,654,402...83,671,474
Ensembl chr13:83,654,406...83,671,420
|
|
G |
Ndufs3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFS3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824
|
|
G |
Ndufs7 |
NADH:ubiquinone oxidoreductase core subunit S7 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFS7 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:9,452,556...9,460,135
Ensembl chr 7:9,450,392...9,460,195
|
|
G |
Ndufs8 |
NADH:ubiquinone oxidoreductase core subunit S8 |
decreases expression |
ISO |
Niclosamide results in decreased expression of NDUFS8 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:201,140,585...201,144,573
Ensembl chr 1:201,140,585...201,144,511
|
|
G |
Ndufv3 |
NADH:ubiquinone oxidoreductase subunit V3 |
increases expression |
ISO |
Niclosamide results in increased expression of NDUFV3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr20:9,612,462...9,621,622
Ensembl chr20:9,612,431...9,623,074
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of and affects the localization of NFATC1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of NFATC1 mRNA] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Niclosamide affects the localization of NFKB1 protein |
CTD |
PMID:26116531 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases phosphorylation multiple interactions |
ISO |
Niclosamide results in decreased phosphorylation of NFKBIA protein Niclosamide inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Niclosamide inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Niclosamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of NFKBIA protein]; Niclosamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:20215516 PMID:26116531 PMID:27492973 PMID:28824321 PMID:33524445 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nkd1 |
NKD inhibitor of WNT signaling pathway 1 |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [Lithium Chloride results in increased expression of NKD1 mRNA] Niclosamide results in increased expression of NKD1 mRNA |
CTD |
PMID:22576131 PMID:24534281 |
|
NCBI chr19:18,476,344...18,549,380
Ensembl chr19:18,476,344...18,549,380
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
multiple interactions decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of NKX3-1 mRNA Niclosamide results in decreased expression of NKX3-1 mRNA |
CTD |
PMID:28500234 |
|
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein] |
CTD |
PMID:33524445 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Notch1 |
notch receptor 1 |
decreases activity multiple interactions |
ISO EXP |
Niclosamide results in decreased activity of NOTCH1 protein Niclosamide inhibits the reaction [Thioacetamide results in increased expression of NOTCH1 mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of NOTCH1 mRNA]] |
CTD |
PMID:19160421 PMID:32961231 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Niclosamide binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:31312845 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ocstamp |
osteoclast stimulatory transmembrane protein |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OCSTAMP mRNA] |
CTD |
PMID:28824321 |
|
NCBI chr 3:154,131,113...154,141,611
Ensembl chr 3:154,132,328...154,136,991
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ORC1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375
|
|
G |
Oscar |
osteoclast associated Ig-like receptor |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OSCAR mRNA] Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of OSCAR mRNA] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr 1:65,607,214...65,615,395
Ensembl chr 1:65,607,410...65,613,758
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression increases expression increases cleavage |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased cleavage of PARP1 protein Niclosamide results in decreased expression of PARP1 protein Niclosamide results in increased expression of PARP1 protein modified form Niclosamide results in increased cleavage of PARP1 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Niclosamide results in increased cleavage of PARP1 protein]; bicalutamide promotes the reaction [Niclosamide results in increased expression of PARP1 protein modified form]; Hydrogen Peroxide promotes the reaction [Niclosamide results in increased cleavage of PARP1 protein]; JUN protein affects the reaction [Niclosamide results in increased cleavage of PARP1 protein]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of PARP1 protein]; WNT7A protein affects the reaction [Niclosamide results in increased cleavage of PARP1 protein] |
CTD |
PMID:24750999 PMID:25174399 PMID:26917416 PMID:28500234 PMID:30258081 PMID:30329025 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pc |
pyruvate carboxylase |
increases expression |
ISO |
Niclosamide results in increased expression of PC mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pfkm |
phosphofructokinase, muscle |
decreases expression |
ISO |
Niclosamide results in decreased expression of PFKM mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
Niclosamide results in increased expression of PHLDA1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
increases expression multiple interactions |
ISO |
Niclosamide results in increased expression of PIK3CA mRNA Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CSGALNACT1 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in decreased expression of HEY1 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of DSCC1 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of ENDOD1 mRNA]; Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] |
CTD |
PMID:27542212 PMID:29843133 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
ISO |
Niclosamide results in increased expression of PKM mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases phosphorylation |
ISO |
Niclosamide results in decreased phosphorylation of POU5F1 protein |
CTD |
PMID:23333246 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
Niclosamide results in increased expression of PPARD mRNA |
CTD |
PMID:22576131 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
decreases expression |
ISO |
Niclosamide results in decreased expression of PPP2CB mRNA |
CTD |
PMID:22576131 |
|
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
ISO |
Niclosamide results in increased expression of PPP2R1A mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Ppp2r1b |
protein phosphatase 2 scaffold subunit A beta |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
decreases expression |
ISO |
Niclosamide results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:22576131 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Ppp2r2c |
protein phosphatase 2, regulatory subunit B, gamma |
decreases expression |
ISO |
Niclosamide results in decreased expression of PPP2R2C mRNA |
CTD |
PMID:22576131 |
|
NCBI chr14:73,846,547...73,931,178
Ensembl chr14:73,846,547...73,931,864
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of PRDM1 mRNA] |
CTD |
PMID:33632240 |
|
NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Prkcq |
protein kinase C, theta |
increases expression |
ISO |
Niclosamide results in increased expression of PRKCQ mRNA |
CTD |
PMID:22576131 |
|
NCBI chr17:67,246,394...67,379,049
Ensembl chr17:67,246,394...67,378,704
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
Niclosamide results in increased expression of PTEN mRNA |
CTD |
PMID:29843133 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rad54l |
RAD54 like |
increases expression |
ISO |
Niclosamide results in increased expression of RAD54L mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases phosphorylation decreases expression |
ISO |
Niclosamide analog results in decreased phosphorylation of RAF1 protein Niclosamide analog results in decreased expression of RAF1 protein; Niclosamide results in decreased expression of RAF1 protein |
CTD |
PMID:28284560 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
ISO EXP |
Niclosamide affects the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of RELA protein modified form] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of RELA protein modified form] Imatinib Mesylate promotes the reaction [Niclosamide results in decreased expression of RELA protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of RELA protein]; Niclosamide inhibits the reaction [TNF protein results in increased activity of RELA protein]; Niclosamide inhibits the reaction [WNT3A protein affects the localization of RELA protein]; Niclosamide promotes the reaction [Imatinib Mesylate results in decreased expression of RELA protein]; Niclosamide results in decreased phosphorylation of and affects the localization of RELA protein |
CTD |
PMID:20215516 PMID:26116531 PMID:26643609 PMID:27492973 PMID:28318631 PMID:28824321 PMID:33524445 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhof |
ras homolog family member F, filopodia associated |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:33,422,375...33,446,689
Ensembl chr12:33,431,280...33,446,703
|
|
G |
Ripor3 |
RIPOR family member 3 |
increases expression |
ISO |
Niclosamide results in increased expression of FAM65C mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 3:156,687,253...156,760,524
Ensembl chr 3:156,687,517...156,715,061
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of ROCK1 mRNA; Niclosamide results in decreased expression of ROCK1 protein |
CTD |
PMID:29251334 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rps6 |
ribosomal protein S6 |
affects phosphorylation |
ISO |
Niclosamide affects the phosphorylation of RPS6 protein |
CTD |
PMID:27542212 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
Niclosamide results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:27542212 PMID:30258081 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of RRM2 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression |
ISO |
Niclosamide results in decreased expression of RUNX2 mRNA |
CTD |
PMID:28824321 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
decreases expression multiple interactions |
ISO |
Niclosamide results in decreased expression of S100A4 mRNA; Niclosamide results in decreased expression of S100A4 protein Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein] |
CTD |
PMID:21685359 PMID:29733962 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpine2 |
serpin family E member 2 |
multiple interactions |
EXP |
Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE2 mRNA] |
CTD |
PMID:28318631 |
|
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO EXP |
HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; Niclosamide inhibits the reaction [TGFB1 protein promotes the reaction [SMAD3 protein binds to HIPK2 promoter]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] Niclosamide inhibits the reaction [Doxorubicin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:28318631 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions decreases expression |
ISO EXP |
Niclosamide inhibits the reaction [Doxorubicin results in increased expression of SNAI1 mRNA] Niclosamide results in decreased expression of SNAI1 mRNA; Niclosamide results in decreased expression of SNAI1 protein Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA] |
CTD |
PMID:26643609 PMID:28318631 PMID:30143678 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions decreases expression |
ISO |
WNT7A protein affects the reaction [Niclosamide results in increased expression of SNAI2 protein] Niclosamide results in decreased expression of SNAI2 protein |
CTD |
PMID:25174399 |
|
NCBI chr11:86,183,800...86,186,109
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein] |
CTD |
PMID:26643609 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation multiple interactions decreases expression |
ISO |
Niclosamide analog results in decreased phosphorylation of STAT3 protein; Niclosamide results in decreased phosphorylation of STAT3 protein Niclosamide affects the reaction [FAS protein mutant form affects the phosphorylation of STAT3 protein] [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; enzalutamide promotes the reaction [Niclosamide results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Niclosamide inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]; Niclosamide inhibits the reaction [IL6 protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Niclosamide inhibits the reaction [STAT3 protein results in decreased susceptibility to enzalutamide]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased phosphorylation of STAT3 protein]; Niclosamide results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of STAT3 protein; Niclosamide results in decreased expression of and results in decreased phosphorylation of STAT3 protein Niclosamide analog results in decreased expression of STAT3 protein; Niclosamide results in decreased expression of STAT3 protein |
CTD |
PMID:23333246 PMID:23894143 PMID:24552774 PMID:25970160 PMID:26116531 PMID:26792726 PMID:28284560 PMID:29031202 PMID:29251334 PMID:30329025 PMID:30779072 PMID:33632240 More...
|
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of TACC3 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Tcf7 |
transcription factor 7 |
multiple interactions |
ISO |
Niclosamide affects the reaction [FAS protein mutant form affects the expression of TCF7 protein] |
CTD |
PMID:33632240 |
|
NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Tcim |
transcriptional and immune response regulator |
increases expression |
ISO |
Niclosamide results in increased expression of TCIM mRNA |
CTD |
PMID:28284560 |
|
NCBI chr16:67,595,762...67,597,055
Ensembl chr16:67,593,410...67,597,581
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]]; HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; Niclosamide inhibits the reaction [TGFB1 protein promotes the reaction [SMAD3 protein binds to HIPK2 promoter]]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of CCL20 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of FAS mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HES1 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY1 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HEY2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of HIPK2 protein]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of ICAM1 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of MMP7 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of RELA protein modified form]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE2 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; Niclosamide inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:28318631 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
increases expression |
ISO |
Niclosamide results in increased expression of TIMP2 mRNA |
CTD |
PMID:30143678 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of TK1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases activity |
ISO |
Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Niclosamide inhibits the reaction [TNF protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of FOXM1 protein]; Niclosamide inhibits the reaction [TNF protein affects the localization of RELA protein]; Niclosamide inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; Niclosamide inhibits the reaction [TNF protein results in increased activity of RELA protein]; Niclosamide inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased expression of BCL2L1 mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased expression of CCND1 mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased expression of MYC mRNA]; Niclosamide inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] Niclosamide results in decreased activity of TNF protein |
CTD |
PMID:20215516 PMID:24561310 PMID:27492973 PMID:28318631 PMID:33524445 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ATP6V0D2 mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ITGAV mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of ITGB3 mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased expression of OSCAR mRNA]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased phosphorylation of AKT1 protein]; Niclosamide inhibits the reaction [TNFSF11 protein results in increased phosphorylation of STAT3 protein] Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ACP5 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of and affects the localization of NFATC1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 protein modified form]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of FOS mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of ITGB3 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of MMP9 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of NFATC1 mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OCSTAMP mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of OSCAR mRNA]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of TRAF6 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK1 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK3 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK8 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of MAPK9 protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of NFKBIA protein]; Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:26792726 PMID:28824321 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression decreases response to substance increases response to substance |
ISO |
[Niclosamide binds to Polyethyleneimine] which results in increased expression of TP53 mRNA; TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA]; TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA]; TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of BBC3 mRNA]; TP53 gene mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP3 protein]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of CASP9 protein]; TP53 gene mutant form promotes the reaction [Niclosamide results in increased cleavage of PARP1 protein]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX12B mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of ALOX5 mRNA]; TP53 protein mutant form inhibits the reaction [Niclosamide results in increased expression of CDKN1A mRNA] [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of adrenic acid; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Docosahexaenoic Acids; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Eicosapentaenoic Acid; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Lysophosphatidylcholines; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of lysophosphatidylethanolamine; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased cleavage of PARP1 protein; [TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased expression of CASP3 protein modified form Niclosamide results in increased expression of TP53 mRNA; Niclosamide results in increased expression of TP53 protein TP53 protein results in decreased susceptibility to Niclosamide TP53 gene mutant form results in increased susceptibility to Niclosamide; TP53 protein mutant form results in increased susceptibility to Niclosamide Niclosamide results in increased expression of TRP53 protein |
CTD |
PMID:22576131 PMID:25988281 PMID:29031202 PMID:30258081 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
ISO |
Niclosamide results in increased expression of TPI1 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
Niclosamide results in decreased expression of TPX2 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Niclosamide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein] results in increased expression of TRAF6 protein] |
CTD |
PMID:28824321 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trip13 |
thyroid hormone receptor interactor 13 |
decreases expression |
ISO |
Niclosamide results in decreased expression of TRIP13 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:29,357,093...29,402,078
Ensembl chr 1:29,357,130...29,402,074
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of TWIST1 protein |
CTD |
PMID:29480568 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions decreases expression |
ISO |
[Niclosamide co-treated with bicalutamide] results in decreased expression of UBE2C mRNA Niclosamide results in decreased expression of UBE2C mRNA |
CTD |
PMID:28500234 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
decreases expression |
ISO |
Niclosamide results in decreased expression of UHRF1 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Utp3 |
UTP3, small subunit processome component |
decreases expression |
ISO |
Niclosamide results in decreased expression of UTP3 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr14:19,515,716...19,517,370
Ensembl chr14:19,515,669...19,517,396
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Niclosamide results in decreased expression of VEGFA mRNA; Niclosamide results in decreased expression of VEGFA protein |
CTD |
PMID:29251334 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions decreases expression |
ISO |
HIPK2 protein inhibits the reaction [Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein]; Niclosamide inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA] Niclosamide results in decreased expression of VIM mRNA; Niclosamide results in decreased expression of VIM protein |
CTD |
PMID:26643609 PMID:28318631 PMID:30143678 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vpreb1a |
V-set pre-B cell surrogate light chain 1A |
decreases expression |
ISO |
Niclosamide results in decreased expression of VPREB1 mRNA |
CTD |
PMID:27226553 |
|
NCBI chr11:84,126,969...84,127,846
Ensembl chr11:84,126,969...84,127,846
|
|
G |
Wnt2b |
Wnt family member 2B |
decreases expression |
ISO |
Niclosamide results in decreased expression of WNT2B mRNA |
CTD |
PMID:22576131 |
|
NCBI chr 2:192,454,226...192,468,599
Ensembl chr 2:192,453,824...192,470,308
|
|
G |
Wnt3 |
Wnt family member 3 |
decreases expression |
ISO |
Niclosamide results in decreased expression of WNT3 mRNA |
CTD |
PMID:22576131 |
|
NCBI chr10:88,680,248...88,724,170
Ensembl chr10:88,680,248...88,724,099
|
|
G |
Wnt3a |
Wnt family member 3A |
multiple interactions decreases expression |
ISO EXP |
Niclosamide inhibits the reaction [WNT3A protein affects the localization of CTNNB1 protein]; Niclosamide inhibits the reaction [WNT3A protein affects the localization of RELA protein]; Niclosamide inhibits the reaction [WNT3A protein results in increased stability of CTNNB1 protein] Niclosamide inhibits the reaction [Thioacetamide results in increased expression of WNT3A mRNA]; Poloxamer promotes the reaction [Niclosamide inhibits the reaction [Thioacetamide results in increased expression of WNT3A mRNA]] Niclosamide results in decreased expression of WNT3A mRNA |
CTD |
PMID:19772353 PMID:22576131 PMID:27492973 PMID:32961231 |
|
NCBI chr10:44,034,174...44,078,463
Ensembl chr10:44,034,194...44,078,324
|
|
G |
Wnt7a |
Wnt family member 7A |
increases response to substance multiple interactions decreases activity |
ISO |
WNT7A protein results in increased susceptibility to Niclosamide WNT7A protein affects the reaction [Niclosamide results in increased cleavage of CASP3 protein]; WNT7A protein affects the reaction [Niclosamide results in increased cleavage of PARP1 protein]; WNT7A protein affects the reaction [Niclosamide results in increased expression of CDH1 protein]; WNT7A protein affects the reaction [Niclosamide results in increased expression of SNAI2 protein] Niclosamide results in decreased activity of WNT7A protein |
CTD |
PMID:25174399 |
|
NCBI chr 4:123,863,108...123,908,981
Ensembl chr 4:123,863,108...123,908,981
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
Niclosamide results in decreased expression of XIAP protein |
CTD |
PMID:20215516 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zfp36 |
zinc finger protein 36 |
increases expression |
ISO |
Niclosamide results in increased expression of ZFP36 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|
G |
Zic2 |
Zic family member 2 |
increases expression |
ISO |
Niclosamide results in increased expression of ZIC2 mRNA |
CTD |
PMID:28284560 |
|
NCBI chr15:99,576,697...99,581,522
Ensembl chr15:99,576,697...99,581,522
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1 protein affects the susceptibility to nilotinib |
CTD |
PMID:28623111 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
multiple interactions |
ISO |
nilotinib inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; nilotinib inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]; nilotinib inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine] |
CTD |
PMID:19841739 |
|
NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects response to substance |
ISO |
ABCG2 protein affects the susceptibility to nilotinib |
CTD |
PMID:24954033 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions decreases phosphorylation |
ISO |
[nilotinib co-treated with Arsenic Trioxide] results in decreased phosphorylation of ABL1 protein; nilotinib inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; nilotinib inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]; nilotinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; nilotinib inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein] nilotinib results in decreased phosphorylation of ABL1 protein; nilotinib results in decreased phosphorylation of ABL1 protein mutant form |
CTD |
PMID:16849647 PMID:19878872 PMID:23883479 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
nilotinib results in increased phosphorylation of ACACA protein |
CTD |
PMID:23707608 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
nilotinib results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with nilotinib] affects the expression of AP2M1 mRNA |
CTD |
PMID:28786057 |
|
NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions decreases expression |
ISO |
Arsenic Trioxide promotes the reaction [nilotinib results in decreased expression of ATF6 protein] |
CTD |
PMID:23883479 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
nilotinib inhibits the reaction [Folic Acid results in increased expression of BAX protein] nilotinib inhibits the reaction [Cyclosporine results in increased expression of BAX mRNA]; nilotinib inhibits the reaction [Cyclosporine results in increased expression of BAX protein] |
CTD |
PMID:31593741 PMID:33710703 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
nilotinib results in decreased expression of BCL2 protein |
CTD |
PMID:26549707 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
multiple interactions decreases phosphorylation |
ISO |
nilotinib inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; nilotinib inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] nilotinib results in decreased phosphorylation of BCR protein mutant form |
CTD |
PMID:16849647 PMID:19878872 |
|
NCBI chr20:13,471,679...13,596,497
Ensembl chr20:13,471,668...13,597,016
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
nilotinib results in decreased expression of C3 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression increases activity |
ISO EXP |
nilotinib results in increased cleavage of CASP3 protein nilotinib inhibits the reaction [Cyclosporine results in increased expression of CASP3 mRNA]; nilotinib inhibits the reaction [Cyclosporine results in increased expression of CASP3 protein] nilotinib results in increased expression of CASP3 protein nilotinib inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [nilotinib results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [nilotinib results in increased cleavage of CASP3 protein] nilotinib results in increased activity of CASP3 protein |
CTD |
PMID:23707608 PMID:23883479 PMID:26549707 PMID:31593741 PMID:32771489 PMID:33710703 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity increases cleavage |
ISO |
nilotinib results in increased activity of CASP7 protein nilotinib results in increased cleavage of CASP7 protein |
CTD |
PMID:23707608 PMID:23883479 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
nilotinib results in increased cleavage of CASP9 protein |
CTD |
PMID:26549707 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cltc |
clathrin heavy chain |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with nilotinib] affects the expression of CLTC mRNA |
CTD |
PMID:28786057 |
|
NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
decreases phosphorylation multiple interactions |
ISO |
nilotinib results in decreased phosphorylation of CRKL protein [nilotinib co-treated with Arsenic Trioxide] results in decreased phosphorylation of CRKL protein; nilotinib inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19878872 PMID:23883479 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
nilotinib results in increased expression of DDIT3 mRNA Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of DDIT3 mRNA] |
CTD |
PMID:23883479 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
affects phosphorylation decreases expression |
ISO |
nilotinib decreased expression of Ddr1 in 3T3 and GD25 cells nilotinib inhibits collagen mediated DDR1 tyrosine phosphorylation in human cancer cell lines nilotinib decreases expression of DDR1 mRNA and protein in human pituitary adenoma cells |
RGD |
PMID:28199848 PMID:29438985 PMID:26286316 |
RGD:151347403, RGD:151347685, RGD:11065574 |
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with nilotinib] affects the expression of DNM2 mRNA |
CTD |
PMID:28786057 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
increases expression multiple interactions |
ISO |
nilotinib results in increased expression of EDEM1 mRNA Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of EDEM1 mRNA] |
CTD |
PMID:23883479 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
nilotinib results in decreased expression of ESR1 protein |
CTD |
PMID:32771489 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
nilotinib results in decreased expression of EYA1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Fcer1g |
Fc epsilon receptor Ig |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with nilotinib] affects the expression of FCER1G mRNA |
CTD |
PMID:28786057 |
|
NCBI chr13:83,649,447...83,654,215
Ensembl chr13:83,649,449...83,671,443
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
nilotinib results in increased expression of FOS mRNA; nilotinib results in increased expression of FOS protein Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of FOS mRNA]; Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of FOS protein] |
CTD |
PMID:23883479 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxc2 |
forkhead box C2 |
decreases expression |
ISO |
nilotinib results in decreased expression of FOXC2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of GCLM mRNA] |
CTD |
PMID:23883479 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion multiple interactions |
ISO EXP |
nilotinib results in increased secretion of GPT protein nilotinib inhibits the reaction [Cyclosporine results in increased activity of GPT protein] |
CTD |
PMID:29655783 PMID:33710703 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
nilotinib inhibits the reaction [Cyclosporine results in decreased activity of GSR protein] |
CTD |
PMID:33710703 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression multiple interactions |
ISO |
nilotinib results in decreased expression of HDC mRNA nilotinib inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] |
CTD |
PMID:16849647 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
nilotinib inhibits the reaction [Cyclosporine results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:33710703 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxb7 |
homeo box B7 |
increases expression |
ISO |
nilotinib results in increased expression of HOXB7 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034
|
|
G |
Hoxb9 |
homeo box B9 |
increases expression |
ISO |
nilotinib results in increased expression of HOXB9 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
ISO |
nilotinib results in increased expression of HSPA5 mRNA Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of HSPA5 mRNA] |
CTD |
PMID:23883479 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
nilotinib inhibits the reaction [Folic Acid results in increased expression of IL18 protein] |
CTD |
PMID:31593741 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; nilotinib inhibits the reaction [Folic Acid results in increased expression of IL1B protein] nilotinib inhibits the reaction [Cyclosporine results in increased expression of IL1B protein] |
CTD |
PMID:28125915 PMID:31593741 PMID:33710703 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
EXP |
nilotinib inhibits the reaction [Cyclosporine results in decreased expression of IL2 protein] |
CTD |
PMID:33710703 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
nilotinib inhibits the reaction [Cyclosporine results in increased expression of IL6 protein] |
CTD |
PMID:33710703 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of JUN mRNA]; Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of JUN protein]; nilotinib results in increased expression of and results in increased phosphorylation of JUN protein nilotinib results in increased expression of JUN mRNA; nilotinib results in increased expression of JUN protein |
CTD |
PMID:23883479 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
nilotinib results in increased expression of JUNB mRNA; nilotinib results in increased expression of JUNB protein Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of JUNB mRNA]; Arsenic Trioxide promotes the reaction [nilotinib results in increased expression of JUNB protein] |
CTD |
PMID:23883479 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity decreases expression multiple interactions |
ISO |
nilotinib results in decreased activity of KCNH2 protein nilotinib results in decreased expression of KCNH2 protein modified form N-butanoylsphingosine inhibits the reaction [nilotinib results in decreased expression of KCNH2 protein modified form]; nilotinib results in decreased expression of and results in decreased activity of KCNH2 protein |
CTD |
PMID:23707608 PMID:35680041 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
decreases expression |
ISO |
nilotinib results in decreased expression of MEOX1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
nilotinib results in decreased expression of MESP2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Neurog2 |
neurogenin 2 |
increases expression |
ISO |
nilotinib results in increased expression of NEUROG2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 2:216,092,641...216,095,276
Ensembl chr 2:216,093,363...216,094,154
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
nilotinib inhibits the reaction [Cyclosporine results in decreased expression of NFE2L2 protein] |
CTD |
PMID:33710703 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
nilotinib inhibits the reaction [Cyclosporine results in decreased expression of NFKBIA mRNA] |
CTD |
PMID:33710703 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
nilotinib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] |
CTD |
PMID:21473879 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Olig3 |
oligodendrocyte transcription factor 3 |
increases expression |
ISO |
nilotinib results in increased expression of OLIG3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
nilotinib results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [nilotinib results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [nilotinib results in increased cleavage of PARP1 protein] |
CTD |
PMID:26549707 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax3 |
paired box 3 |
decreases expression |
ISO |
nilotinib results in decreased expression of PAX3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Pax6 |
paired box 6 |
increases expression |
ISO |
nilotinib results in increased expression of PAX6 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
nilotinib inhibits the reaction [Folic Acid results in increased expression of RELA protein] |
CTD |
PMID:31593741 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sacs |
sacsin molecular chaperone |
increases expression |
ISO |
nilotinib results in increased expression of SACS mRNA |
CTD |
PMID:29901742 |
|
NCBI chr15:35,285,783...35,370,335
Ensembl chr15:35,285,782...35,370,335
|
|
G |
Sec24b |
SEC24 homolog B, COPII coat complex component |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with nilotinib] affects the expression of SEC24B mRNA |
CTD |
PMID:28786057 |
|
NCBI chr 2:218,562,670...218,632,753
Ensembl chr 2:218,562,676...218,632,699
|
|
G |
Tcf15 |
transcription factor 15 |
decreases expression |
ISO |
nilotinib results in decreased expression of TCF15 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:140,638,984...140,644,766
Ensembl chr 3:140,638,984...140,644,766
|
|
G |
Tff1 |
trefoil factor 1 |
decreases expression |
ISO |
nilotinib results in decreased expression of TFF1 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
nilotinib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TGFB1 mRNA] |
CTD |
PMID:21473879 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
nilotinib inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA] nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; nilotinib inhibits the reaction [Folic Acid results in increased expression of TNF protein] |
CTD |
PMID:21473879 PMID:28125915 PMID:31593741 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf12 |
TNF superfamily member 12 |
multiple interactions |
ISO |
nilotinib inhibits the reaction [Folic Acid results in increased expression of TNFSF12 protein] |
CTD |
PMID:31593741 |
|
NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213
|
|
G |
Tp53 |
tumor protein p53 |
increases secretion |
ISO |
nilotinib results in increased secretion of TP53 protein |
CTD |
PMID:29370077 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
nilotinib results in decreased activity of UGT1A1 protein |
CTD |
PMID:26875642 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Uncx |
UNC homeobox |
decreases expression |
ISO |
nilotinib results in decreased expression of UNCX mRNA |
CTD |
PMID:31711903 |
|
NCBI chr12:15,092,779...15,097,300
Ensembl chr12:15,092,784...15,097,300
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
nilotinib results in increased expression of XBP1 mRNA alternative form |
CTD |
PMID:23883479 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein osimertinib decreases phosphorylation of AKT1 protein in lung |
CTD RGD |
PMID:30145802 PMID:30623574 PMID:30993382 PMID:32276600 |
RGD:151357000 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO |
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form] |
CTD |
PMID:28237877 PMID:31916386 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases response to substance |
ISO |
CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form] CAT protein results in decreased susceptibility to osimertinib |
CTD |
PMID:28237877 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
osimertinib inhibits the reaction [Dronabinol results in decreased expression of and results in decreased activity of CFTR protein] |
CTD |
PMID:29928919 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30623574 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases activity decreases phosphorylation |
ISO |
osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein osimertinib results in decreased activity of EGFR protein osimertinib decreases phosphorylation of EGFR protein in lung |
CTD RGD |
PMID:28237877 PMID:30145802 PMID:30623574 PMID:30993382 PMID:32276600 |
RGD:151357000 |
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
ISO |
osimertinib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein] |
CTD |
PMID:30623574 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:29928919 PMID:30623574 PMID:30993382 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:29928919 PMID:30623574 PMID:30993382 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
osimertinib decreases expression of MCL1 protein in lung |
RGD |
PMID:31301315 PMID:32276600 |
RGD:151356917, RGD:151357000 |
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein |
CTD |
PMID:31916386 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression multiple interactions increases cleavage |
ISO |
osimertinib results in increased expression of PARP1 protein modified form [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form] |
CTD |
PMID:28237877 PMID:30171258 PMID:31916386 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
osimertinib results in decreased expression of SQSTM1 protein |
CTD |
PMID:30145802 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:30623574 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
decreases response to substance multiple interactions affects response to substance |
ISO |
TWIST1 protein results in decreased susceptibility to osimertinib [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein] TWIST1 protein affects the susceptibility to osimertinib |
CTD |
PMID:30171258 PMID:30993382 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions decreases activity |
ISO |
osimertinib inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone] osimertinib results in decreased activity of UGT1A1 protein |
CTD |
PMID:34044055 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
decreases activity |
ISO |
osimertinib results in decreased activity of UGT1A3 protein |
CTD |
PMID:34044055 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases activity |
ISO |
osimertinib results in decreased activity of UGT1A6 protein |
CTD |
PMID:34044055 |
|
NCBI chr 9:88,747,229...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases activity |
ISO |
osimertinib results in decreased activity of UGT2B7 protein |
CTD |
PMID:34044055 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
affects transport |
ISO |
ABCA8 protein affects the transport of p-Aminohippuric Acid |
CTD |
PMID:12379217 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of p-Aminohippuric Acid |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Slc17a3 |
solute carrier family 17 member 3 |
affects transport |
ISO |
SLC17A3 gene SNP affects the transport of p-Aminohippuric Acid |
CTD |
PMID:21282933 |
|
NCBI chr17:41,270,804...41,300,132
Ensembl chr17:41,270,812...41,295,256
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions increases uptake |
ISO |
Barium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Diethyl Pyrocarbonate inhibits the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Ouabain promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Potassium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:15284287 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
p-Aminohippuric Acid inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine] |
CTD |
PMID:15496291 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a20 |
solute carrier family 22 member 20 |
multiple interactions |
ISO |
p-Aminohippuric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16478971 |
|
NCBI chr 1:203,257,374...203,273,848
Ensembl chr 1:203,257,374...203,273,822
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
affects transport increases import increases uptake multiple interactions increases export increases secretion |
ISO EXP |
SLC22A6 protein affects the transport of p-Aminohippuric Acid SLC22A6 protein results in increased import of p-Aminohippuric Acid SLC22A6 protein results in increased uptake of p-Aminohippuric Acid; SLC22A6 results in increased uptake of p-Aminohippuric Acid 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; 9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; adefovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Amitriptyline inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I inhibits the reaction [SLC22A6 results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol A promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol F promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefaclor inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefdinir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefotiam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftibuten inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftizoxime inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cephaloridine inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Chlorides promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; chlorpyrifos-methyl inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cimetidine inhibits the reaction [SLC22A6 protein affects the transport of p-Aminohippuric Acid]; cyazofamid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Diazepam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fenitrothion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fluorescein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Glutarates promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; glutaric acid promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; Malathion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Mianserin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased susceptibility to [mercuric oxide co-treated with Acetylcysteine]]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid analog]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of 2,4-Dichlorophenoxyacetic Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Uric Acid]; Penicillin G inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Quercetin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Resveratrol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Sulfobromophthalein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Triazolam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid]; Unithiol promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid] p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of ochratoxin A]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorohexanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorooctanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid] |
CTD |
PMID:10336520 PMID:11602689 PMID:12472777 PMID:12606766 PMID:15200431 PMID:15284288 PMID:15496291 PMID:16098483 PMID:17255469 PMID:17353191 PMID:18216144 PMID:19605544 PMID:19643159 PMID:19915082 PMID:21244849 PMID:21256917 PMID:21561794 PMID:23856525 PMID:27377006 PMID:27989701 PMID:28629854 PMID:28890383 PMID:32003934 PMID:32305507 More...
|
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases uptake |
ISO |
SLC22A7 protein results in increased uptake of p-Aminohippuric Acid |
CTD |
PMID:12065749 PMID:15901346 PMID:21256917 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions increases uptake affects transport increases export |
ISO EXP |
Cimetidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Enalapril inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Ibuprofen inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; tenoxicam inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] SLC22A8 protein affects the transport of p-Aminohippuric Acid SLC22A8 results in increased export of p-Aminohippuric Acid aristolochic acid I promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]; estrone sulfate promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid] p-Aminohippuric Acid inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine] |
CTD |
PMID:10224140 PMID:11306713 PMID:15100168 PMID:15319347 PMID:16098483 PMID:19643159 More...
|
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of palmidrol |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Apob |
apolipoprotein B |
affects folding |
ISO |
palmidrol affects the folding of APOB protein |
CTD |
PMID:16115474 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
palmidrol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Cldn3 |
claudin 3 |
multiple interactions decreases expression |
ISO |
[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA palmidrol results in decreased expression of CLDN3 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
palmidrol results in decreased expression of CLDN5 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
[rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:17558434 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects binding multiple interactions |
ISO EXP |
palmidrol binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:10617657 PMID:10688601 PMID:17558434 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
![JBrowse link JBrowse link]() |